- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic lymphocytic leukaemia or Small lymphocytic lymphoma
- Meeting Date: March 2024
- Public Summary Document (PSD) March 2024 PBAC Meeting - (PDF 1.1MB)
- Public Summary Document (PSD) March 2024 PBAC Meeting - (Word 470KB)
Ibrutinib – March 2024
Ibrutinib: Capsule 140 mg, Tablet 280 mg, Tablet 420 mg; Imbruvica®
Last updated
30 May 2025